reports
Certara Simcyp® Simulator Becomes First and Only Software Platform to ...
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between ...
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...
Certara to Report Second Quarter 2025 Financial Results on August 6th,...
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to It is recommended to register at least one day in advance. A live and archived webc...
Certara Announces Expansion of Clinical Technology Collaboration with ...
Certara Announces Expansion of Clinical Technology Collaboration with Merck Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement...
Certara Reports First Quarter 2025 Financial Results
Certara Reports First Quarter 2025 Financial Results Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue w...
Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be availa...
- Dave Nicoski
- Ross LaDuke
BKD BROOKDALE SENIOR LIVING INC.
STRL STERLING CONSTRUCTION COMPANY INC.
SLP SIMULATIONS PLUS
MKTX MARKETAXESS HOLDINGS INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
HII HUMANA INC.
HCA HUNTINGTON INGALLS INDUSTRIES INC.
GD HCA HEALTHCARE INC
DLTR GENERAL DYNAMICS CORPORATION
DG DOLLAR TREE INC.
CVGW DOLLAR GENERAL CORPORATION
CNC CALAVO GROWERS INC.
CL CENTENE CORPORATION
CACI COLGATE-PALMOLIVE COMPANY
FDP CACI INTERNATIONAL INC CLASS A
SJW FRESH DEL MONTE PRODUCE INC.
LKO SJW GROUP
FIZZ LAKES OIL N.L.
CELH NATIONAL BEVERAGE CORP.
PAGS CELSIUS HOLDINGS INC.
STNE PAGSEGURO DIGITAL LTD
LHX STONECO
CERT L3HARRIS TECHNOLOGIES INC
MASS CERTARA
CTGO 908 DEVICES
NTST CONTANGO ORE INC.
YOU NETSTREIT CORP
HUM CLEAR SECURE INC
HAMILTON U.S. MID-CAP FINANCIALS ETF
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developer...
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its ™ solution designed to help biopharmaceutical companies lead the transition ignited by the The Roadmap marks a pivotal moment in drug development. Companies that act now...
Certara Reports Preliminary First Quarter 2025 Financial Results; Anno...
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which ...
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceut...
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numero...
Certara Appoints Dr. Adrian McKemey as President of Drug Development S...
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions McKemey joins Certara to accelerate growth of its strategic drug development solutions RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA a...
Certara Reports Fourth Quarter 2024 Financial Results
Certara Reports Fourth Quarter 2024 Financial Results Issues Full Year 2025 Financial Guidance RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 ...
Certara to Report Fourth Quarter and Full Year 2024 Financial Results ...
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to . ...
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
- Dave Nicoski
- Ross LaDuke
ZBH ZIMMER BIOMET HOLDINGS INC.
SLB.N SCHLUMBERGER NV
CNHI CNH INDUSTRIAL NV
WBA WALGREENS BOOTS ALLIANCE INC
ULTA ULTA BEAUTY INC
SLP SIMULATIONS PLUS
PCRX PACIRA BIOSCIENCES INC.
PBF PBF ENERGY INC. CLASS A
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
HXL HEXCEL CORPORATION
DAN DANA INCORPORATED
CVI CVR ENERGY INC.
AGCO AGCO CORPORATION
ACAD ACADIA PHARMACEUTICALS INC.
ALV ALLIANZ SE
MUR MURPHY OIL CORPORATION
BRKS BROOKS AUTOMATION INC.
HP HELMERICH & PAYNE INC.
PTEN PATTERSON-UTI ENERGY INC.
VLO VALERO ENERGY CORPORATION
HI HILLENBRAND INC.
INGR-R-A INGRA D.D.
EYE NATIONAL VISION HOLDINGS
CPRI CAPRI HOLDINGS LIMITED
TW TRADEWEB MARKETS INC. CLASS A
REEMF RARE ELEMENT RESOURCES
NVST ENVISTA HOLDINGS
PGNY PROGYNY
CERT CERTARA
VAL VALARIS LTD
BBWI BATH & BODY WORKS INC
CIVI CIVITAS RESOURCES INC
INVX INNOVEX INTERNATIONAL INC
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financia...
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be as follow...
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Confe...
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Company management will present at 5:15PM PT on Wednesday, January 15th, 2025. A live webcast of the event will be available on Certara’s investor relations website at and will be available for replay for at least 30 days thereafter. About CertaraCertara accelerates medicine...
Certara Showcases 2024 Research Wins With Over 100 Papers Published
Certara Showcases 2024 Research Wins With Over 100 Papers Published The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 list, which highlights the top 2% of the most cited scientists across the globe. Stanford/Elsevier's Top 2% Scientist RankingNow in it...
Certara Reports Third Quarter 2024 Financial Results
Certara Reports Third Quarter 2024 Financial Results Updates Full Year 2024 Financial Guidance RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 mill...
Certara to Participate in the Stephens Annual Investment Conference
Certara to Participate in the Stephens Annual Investment Conference RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. Company management will present at 10:00AM CT on Thursday, November 21st, 2024. A live webcast of the event will be available on Certara’s investor relations website at and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.